Life Sciences

Sanctura journal ad misleading, FDA says

Pharma Compliance Alert, February 4, 2009

A professional journal advertisement for Sanctura, co-promoted by Allergan and Indevus Pharmaceuticals, misbrands the drug, according to an FDA warning letter posted January 29.

The journal ad makes unsubstantiated superiority claims for the drug, omits and minimizes material risk information, and overstates the efficacy of Sanctura, the FDA says.

Comments

0 comments on “Sanctura journal ad misleading, FDA says

 

Most Popular